T-Prime Labs Overview
- Year Founded
-
2026
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
1
T-Prime Labs General Information
Description
Developer of personalized cancer immunotherapies designed to target tumor-specific peptides presented on major histocompatibility complex molecules for precision oncology treatment. The company is currently operating in Stealth Mode.
Contact Information
Website
www.tprimelabs.comCorporate Office
- 1409 Shrader Street
- Apartment 3
- San Francisco, CA 94117
- United States
Corporate Office
- 1409 Shrader Street
- Apartment 3
- San Francisco, CA 94117
- United States
T-Prime Labs Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Nov-2026 | Completed | Stealth |
T-Prime Labs Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
T-Prime Labs Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Fifty Years | Venture Capital | Minority |
T-Prime Labs FAQs
-
When was T-Prime Labs founded?
T-Prime Labs was founded in 2026.
-
Where is T-Prime Labs headquartered?
T-Prime Labs is headquartered in San Francisco, CA.
-
What industry is T-Prime Labs in?
T-Prime Labs’s primary industry is Drug Discovery.
-
Is T-Prime Labs a private or public company?
T-Prime Labs is a Private company.
-
What is T-Prime Labs’s current revenue?
The current revenue for T-Prime Labs is .
-
Who are T-Prime Labs’s investors?
Fifty Years has invested in T-Prime Labs.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
